These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology; 1998 Mar; 50(3):645-51. PubMed ID: 9521250 [TBL] [Abstract][Full Text] [Related]
24. Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Finali G; Piccirilli M; Oliani C; Piccinin GL Ital J Neurol Sci; 1992 Mar; 13(2):141-8. PubMed ID: 1592575 [TBL] [Abstract][Full Text] [Related]
25. An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke. Bartolo M; Zucchella C; Capone A; Sandrini G; Pierelli F J Neurol Sci; 2015 Feb; 349(1-2):117-23. PubMed ID: 25592412 [TBL] [Abstract][Full Text] [Related]
26. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668 [TBL] [Abstract][Full Text] [Related]
27. Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Tolbert SR; Fuller MA Ann Pharmacother; 1996 Oct; 30(10):1122-9. PubMed ID: 8998375 [TBL] [Abstract][Full Text] [Related]
29. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M; PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105 [TBL] [Abstract][Full Text] [Related]
30. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262 [TBL] [Abstract][Full Text] [Related]
31. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial. Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488 [TBL] [Abstract][Full Text] [Related]
32. Global measures: utility in defining and measuring treatment response in dementia. Reisberg B Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241 [TBL] [Abstract][Full Text] [Related]
33. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. van Dongen MC; van Rossum E; Kessels AG; Sielhorst HJ; Knipschild PG J Am Geriatr Soc; 2000 Oct; 48(10):1183-94. PubMed ID: 11037003 [TBL] [Abstract][Full Text] [Related]
34. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895 [TBL] [Abstract][Full Text] [Related]
35. Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. Senin U; Abate G; Fieschi C; Gori G; Guala A; Marini G; Villardita C; Parnetti L Eur Neuropsychopharmacol; 1991 Dec; 1(4):511-7. PubMed ID: 1822317 [TBL] [Abstract][Full Text] [Related]
36. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Sano M; Ernesto C; Thomas RG; Klauber MR; Schafer K; Grundman M; Woodbury P; Growdon J; Cotman CW; Pfeiffer E; Schneider LS; Thal LJ N Engl J Med; 1997 Apr; 336(17):1216-22. PubMed ID: 9110909 [TBL] [Abstract][Full Text] [Related]
38. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744 [TBL] [Abstract][Full Text] [Related]
40. Characteristics of motor vehicle crashes of drivers with dementia of the Alzheimer type. Carr DB; Duchek J; Morris JC J Am Geriatr Soc; 2000 Jan; 48(1):18-22. PubMed ID: 10642016 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]